June MIMS update

We look at some of the recent changes to the medicines landscape, with new products, new indications and safety related changes  New Products Deucravacitinib (Sotyktu) is a small molecule that selectively inhibits the tyrosine kinase 2 (TYK2) enzyme. It binds to the regulatory domain of TYK2, stabilising an inhibitory interaction between the regulatory and the